13 research outputs found
SMN only detected in cerebral spinal fluid samples containing hemoglobin.
<p>The CSF samples obtained from healthy volunteers were concentrated prior to analysis, and the sensitivity of the SMN-ECL immunoassay was 0.3 pg/mL. Hemoglobin was measured using a hemoglobin immunoassay (Bethyl Laboratories E88-135). Approximately 3 pg of SMN correspond to 10,000 ng of hemoglobin in 1 mL of whole blood from a healthy adult. LLQ: lower limit of quantification.</p
SMN protein levels in tissues of C/C-allele and WT mice measured by SMN-ECL and SMN-ELISA.
<p>Protein levels were measured in the spinal cord of C/C-allele and WT mice using (A) SMN-ECL and (B) SMN-ELISA. Both assays showed a statistically significant difference in SMN levels between WT and C/C-allele mice (p < 0.0001). (C) SMN protein levels in the whole blood of C/C-allele, WT and heterozygous mice measured by SMN-ECL.</p
SMN protein levels in SMA patient and control whole blood samples.
<p>(A) SMN levels with respect to age in all subjects. (B) SMN protein levels were measured in SMA patients with 2, 3 and 4 copies of <i>SMN2</i>. In patients over 2 months of age, SMN levels were significantly greater in SMA patient samples with 4 <i>SMN2</i> copies relative to those with 2 and 3 <i>SMN2</i> copies (p = 0.0001). (C) SMN was also measured in three control samples and SMN levels were found to be significantly greater in the control samples relative to levels in SMA patients over 2 months of age (p < 0.0001).</p
SMN protein was found in various cell types in whole blood.
<p>Platelets, red blood cells, PBMCs and reticulocytes were separated by a fractionation procedure.</p
Correlation of SMN protein levels between tissues.
<p>SMN protein levels were correlated in WT and C/C-allele SMA mice between (A) whole blood and brain and (B) whole blood and spinal cord.</p
SMN protein levels in WT and C/C-allele SMA mice of different ages.
<p>SMN protein levels were measured by SMN-ECL at various days post-birth in (A) brain, (B) whole blood, (C) spinal cord, and (D) gastrocnemius muscle.</p
SMN protein levels in capillary and venous blood obtained over time from healthy volunteers did not vary significantly.
<p>Venous (A, B) and capillary (C) whole blood samples were obtained at 0, 4, 6, 24, 48, 72 hours and 1, 2, 3, 4 weeks from five healthy individuals. Fig 2B is an expanded version of Fig 2A. (D) SMN protein levels in capillary blood correlated significantly with SMN levels in venous blood (r<sup>2</sup> = 0.76, p < 0.0001).</p
SMN protein stability in whole blood: short term, long term, and freeze / thaw events.
<p>Whole blood of healthy subjects was used in the study. (A) SMN protein was measured in previously frozen, undiluted whole blood samples incubated at 4°C or at room temperature. (B) SMN protein was measured in undiluted whole blood samples of two subjects stored at -80°C or at -20°C. (C) SMN protein levels were measured in samples of two subjects that went through freeze-thaw cycles. *FDA acceptance criteria (below 85%).</p
Top 13 SMA motor function regressors are markers in two SMA populations.
<p>The top 13 list was compiled based on significant regression to HFMS and other SMA motor outcome measures in the PNCRN natural history study sampleset. The pilot panel of markers tested included 35 top motor analytes identified via the BforSMA study and these 13 analytes represent robust repeat markers in a distinct SMA population.</p
SMA non-motor outcome regressors.
<p>Several markers were identified in the PNCR NHS as regressing to the Children’s Hospital of Philadelphia Test of Strength (CHOP-TOSS), pulmonary function (best FVC), electrophysiology (CMAP and MUNE), strength as measured by knee and elbow flexion and extension(log average MyoEF, MyoKE, MyoKF), parent-reported and child-reported quality of life (PQP and PQC).</p